Balancing benefit and risk of medicines: a systematic review and classification of available methodologies

The need for formal and structured approaches for benefit–risk assessment of medicines is increasing, as is the complexity of the scientific questions addressed before making decisions on the benefit–risk balance of medicines. We systematically collected, appraised and classified available benefit–risk methodologies to facilitate and inform their future use.

[1]  Ortwin Renn,et al.  A Decision‐Analysis Tool for Benefit–Risk Assessment of Nonprescription Drugs , 2013, Journal of clinical pharmacology.

[2]  Tommi Tervonen,et al.  ADDIS: A decision support system for evidence-based medicine , 2013, Decis. Support Syst..

[3]  James J. Chen,et al.  Quantitative Benefit-Risk Analysis for Evaluating Drug Therapies , 2013, Journal of biopharmaceutical statistics.

[4]  R. Varadhan,et al.  A framework for organizing and selecting quantitative approaches for benefit-harm assessment , 2012, BMC Medical Research Methodology.

[5]  Andy Hart,et al.  BRAFO tiered approach for Benefit-Risk Assessment of Foods. , 2012, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[6]  R. Varadhan,et al.  Methods for Benefit and Harm Assessment in Systematic Reviews , 2012 .

[7]  Rosalee S. Hellberg,et al.  Risk-Benefit Analysis of Seafood Consumption: A Review , 2012 .

[8]  Erik Mosekilde,et al.  A Comprehensive Approach to Benefit–Risk Assessment in Drug Development , 2012, Basic & clinical pharmacology & toxicology.

[9]  Tommi Tervonen,et al.  Multicriteria benefit-risk assessment using network meta-analysis. , 2012, Journal of clinical epidemiology.

[10]  I. Buchan,et al.  Population Impact Analysis: a framework for assessing the population impact of a risk or intervention. , 2012, Journal of public health.

[11]  S. Walker,et al.  Standardizing the Benefit-Risk Assessment of New Medicines , 2011, Pharmaceutical Medicine.

[12]  N. Kalogeras,et al.  State of the art in benefit-risk analysis: food microbiology. , 2012, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[13]  Jixian Wang,et al.  Statistical aspects in comparative benefit‐risk assessment: challenges and opportunities for pharmaceutical statisticians , 2012, Pharmaceutical statistics.

[14]  M. Morelle,et al.  Cancer patients’ willingness to pay for blood transfusions at home: results from a contingent valuation study in a French cancer network , 2012, The European Journal of Health Economics.

[15]  Ortwin Renn,et al.  Improving the Decision‐Making Process for Nonprescription Drugs: A Framework for Benefit–Risk Assessment , 2011, Clinical pharmacology and therapeutics.

[16]  A. Sashegyi A Benefit-risk Model to Facilitate DMC-sponsor Communication and Decision Making , 2011 .

[17]  P. Schulz,et al.  Assessing the benefit:risk ratio of a drug - randomized and naturalistic evidence , 2011, Dialogues in clinical neuroscience.

[18]  Tommi Tervonen,et al.  A stochastic multicriteria model for evidence‐based decision making in drug benefit‐risk analysis , 2011, Statistics in medicine.

[19]  Shahrul Mt-Isa,et al.  Weighing benefit-risk of medicines: concepts and approaches. , 2011, Drug discovery today. Technologies.

[20]  B S Levitan,et al.  Development of a Framework for Enhancing the Transparency, Reproducibility and Communication of the Benefit–Risk Balance of Medicines , 2011, Clinical pharmacology and therapeutics.

[21]  B S Levitan,et al.  Application of the BRAT Framework to Case Studies: Observations and Insights , 2011, Clinical pharmacology and therapeutics.

[22]  Lawrence D. Phillips,et al.  Benefit-risk methodology project: work package 2 report: applicability of current tools and processes for regulatory benefit-risk assessment , 2011 .

[23]  Mohsen Sadatsafavi,et al.  A quantitative evaluation of the regulatory assessment of the benefits and risks of rofecoxib relative to naproxen: an application of the incremental net‐benefit framework , 2010, Pharmacoepidemiology and drug safety.

[24]  John Doyle,et al.  A review of quantitative risk-benefit methodologies for assessing drug safety and efficacy-report of the ISPOR risk-benefit management working group. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[25]  A first step to assess harm and benefit in clinical trials in one scale. , 2010, Journal of clinical epidemiology.

[26]  Mark J Sculpher,et al.  Using the incremental net benefit framework for quantitative benefit-risk analysis in regulatory decision-making--a case study of alosetron in irritable bowel syndrome. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[27]  An effective process for making decisions about major operating room purchases. , 2010, AORN journal.

[28]  D. Ouellet Benefit–risk assessment: the use of clinical utility index , 2010, Expert opinion on drug safety.

[29]  L. Citrome Relative vs. absolute measures of benefit and risk: what’s the difference? , 2010, Acta psychiatrica Scandinavica.

[30]  J. Louviere,et al.  Discrete Choice Experiments Are Not Conjoint Analysis , 2010 .

[31]  Net efficacy adjusted for risk: further developments , 2009, Expert opinion on drug safety.

[32]  L Liberti,et al.  Measuring Benefit and Balancing Risk: Strategies for the Benefit–Risk Assessment of New Medicines in a Risk‐Averse Environment , 2009, Clinical pharmacology and therapeutics.

[33]  J. Werth,et al.  The Use of a Clinical Utility Index to Compare Insomnia Compounds: A Quantitative Basis for Benefit–Risk Assessment , 2009, Clinical pharmacology and therapeutics.

[34]  F Reed Johnson,et al.  Are Adult Patients More Tolerant of Treatment Risks Than Parents of Juvenile Patients? , 2009, Risk Analysis.

[35]  L. Phillips,et al.  Multi-criteria analysis: a manual , 2009 .

[36]  Rajesh Krishna,et al.  The Use of Clinical Utility Assessments in Early Clinical Development , 2009, The AAPS Journal.

[37]  Sam Salek,et al.  Benefit-Risk Appraisal of Medicines , 2008 .

[38]  M. García-Sáiz,et al.  Net Efficacy Adjusted for Risk (NEAR): A Simple Procedure for Measuring Risk:Benefit Balance , 2008, PloS one.

[39]  E. Dorsey,et al.  Quantitative risk-benefit analysis of natalizumab , 2008, Neurology.

[40]  Christy Chuang-Stein,et al.  Measures for Conducting Comparative Benefit: Risk Assessment , 2008 .

[41]  I Persson,et al.  What is the harm-benefit ratio of Cox-2 inhibitors? , 2008, International journal of epidemiology.

[42]  C. Dewa,et al.  A Clinician's Guide to Correct Cost-Effectiveness Analysis: Think Incremental Not Average , 2008, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[43]  Mandy Ryan,et al.  Using discrete choice experiments to value health and health care , 2008 .

[44]  Lakhmi C. Jain,et al.  Introduction to Bayesian Networks , 2008 .

[45]  J. Figueira,et al.  A survey on stochastic multicriteria acceptability analysis methods , 2008 .

[46]  Sam Salek,et al.  A quantitative approach to benefit‐risk assessment of medicines – part 1: the development of a new model using multi‐criteria decision analysis , 2007, Pharmacoepidemiology and drug safety.

[47]  Louis P Garrison,et al.  Assessing a structured, quantitative health outcomes approach to drug risk-benefit analysis. , 2007, Health affairs.

[48]  A. Brennan,et al.  PAR15 USING MIXED TREATMENT COMPARISONS AND METAREGRESSION TO PERFORM INDIRECT COMPARISONS TO ESTIMATE THE EFFICACY OF BIOLOGIC TREATMENTS IN RHEUMATOID ARTHRITIS , 2007 .

[49]  E Ferguson,et al.  From comparative risk assessment to multi-criteria decision analysis and adaptive management: recent developments and applications. , 2006, Environment international.

[50]  F. Sassi Calculating QALYs, comparing QALY and DALY calculations. , 2006, Health policy and planning.

[51]  Alex J. Sutton,et al.  Multiparameter evidence synthesis in epidemiology and medical decision‐making: current approaches , 2006 .

[52]  J.,et al.  Markov Models in Medical Decision Making : A Practical Guide , 2006 .

[53]  K. Rich,et al.  A review of economic tools for the assessment of animal disease outbreaks. , 2005, Revue scientifique et technique.

[54]  Linda S. Deal,et al.  Age-Specific Questionnaires Distinguish GERD Symptom Frequency and Severity in Infants and Young Children: Development and Initial Validation , 2005, Journal of pediatric gastroenterology and nutrition.

[55]  M. A. Best Bayesian Approaches to Clinical Trials and Health‐Care Evaluation , 2005 .

[56]  Nicola J Cooper,et al.  A Bayesian approach to evaluating net clinical benefit allowed for parameter uncertainty. , 2005, Journal of clinical epidemiology.

[57]  G. Lu,et al.  Combination of direct and indirect evidence in mixed treatment comparisons , 2004, Statistics in medicine.

[58]  Larry D Lynd,et al.  Advances in risk-benefit evaluation using probabilistic simulation methods: an application to the prophylaxis of deep vein thrombosis. , 2004, Journal of clinical epidemiology.

[59]  Nicola J Cooper,et al.  Benefits and harms associated with hormone replacement therapy: clinical decision analysis , 2004, BMJ : British Medical Journal.

[60]  E M Faustman,et al.  Comparative Risk and Policy Analysis in Environmental Health , 2003, Risk analysis : an official publication of the Society for Risk Analysis.

[61]  Juhaeri Juhaeri,et al.  Benefit‐risk analysis: examples using quantitative methods , 2003, Pharmacoepidemiology and drug safety.

[62]  I. Buchan,et al.  Communicating risks at the population level: application of population impact numbers , 2003, BMJ : British Medical Journal.

[63]  Juhaeri Juhaeri,et al.  Benefit‐risk analysis: a proposal using quantitative methods , 2003, Pharmacoepidemiology and drug safety.

[64]  Richard D. Smith Construction of the contingent valuation market in health care: a critical assessment. , 2003, Health economics.

[65]  Y. Shih Bayesian approach in pharmacoeconomics: relevance to decision-makers , 2003, Expert review of pharmacoeconomics & outcomes research.

[66]  Anne Whitehead,et al.  An illustration of the modelling of cost and efficacy data from a clinical trial , 2003, Statistics in medicine.

[67]  T. Lumley Network meta‐analysis for indirect treatment comparisons , 2002, Statistics in medicine.

[68]  A. Dobson,et al.  Impact numbers in health policy decisions , 2002, Journal of epidemiology and community health.

[69]  A. Dobson,et al.  Impact numbers: measures of risk factor impact on the whole population from case-control and cohort studies , 2002, Journal of epidemiology and community health.

[70]  T J Ulahannan,et al.  Decision Making in Health and Medicine: Integrating Evidence and Values , 2002 .

[71]  Christopher J Cates,et al.  Simpson's paradox and calculation of number needed to treat from meta-analysis , 2002, BMC medical research methodology.

[72]  Andrew H Briggs,et al.  Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. , 2002, Annual review of public health.

[73]  A Ludbrook,et al.  Use of discrete choice experiments to elicit preferences , 2001, Quality in health care : QHC.

[74]  C. Mulrow,et al.  Current methods of the US Preventive Services Task Force: a review of the process. , 2001, American journal of preventive medicine.

[75]  Finn V. Jensen,et al.  Bayesian Networks and Decision Graphs , 2001, Statistics for Engineering and Information Science.

[76]  Adrian F. M. Smith,et al.  Evidence-based medicine as Bayesian decision-making. , 2000, Statistics in medicine.

[77]  D. Hensher,et al.  Stated Choice Methods: Analysis and Applications , 2000 .

[78]  A. McAlearney,et al.  Quality-adjusted life-years and other health indices: a comparative analysis. , 1999, Clinical therapeutics.

[79]  C Cates,et al.  Confidence intervals for the number needed to treat , 1999 .

[80]  G H Guyatt,et al.  Users' guides to the medical literature: XVI. How to use a treatment recommendation. Evidence-Based Medicine Working Group and the Cochrane Applicability Methods Working Group. , 1999, JAMA.

[81]  J Beckmann Basic aspects of risk-benefit analysis. , 1999, Seminars in thrombosis and hemostasis.

[82]  W. Ried,et al.  QALYs versus HYEs--what's right and what's wrong. A review of the controversy. , 1998, Journal of health economics.

[83]  Ralph L. Keeney,et al.  Book Reviews : Scientific Opportunities and Public Needs: Improv ing Priority Setting and Public Input at the National Institutes of Health. Institute of Medicine. Washington, DC: National Academy Press, 1998, 136 pages, $26.00 , 1998 .

[84]  H. Korting,et al.  The Benefit/Risk Ratio: A Handbook for the Rational Use of Potentially Hazardous Drugs , 1998 .

[85]  Risto Lahdelma,et al.  SMAA - Stochastic multiobjective acceptability analysis , 1998, Eur. J. Oper. Res..

[86]  M Ryan,et al.  Using conjoint analysis to assess women's preferences for miscarriage management. , 1997, Health economics.

[87]  K A Schulman,et al.  Mathematical Models in Decision Analysis , 1997, Infection Control & Hospital Epidemiology.

[88]  M. Schulzer,et al.  'Unqualified success' and 'unmitigated failure': number-needed-to-treat-related concepts for assessing treatment efficacy in the presence of treatment-induced adverse events. , 1996, International journal of epidemiology.

[89]  R. Gelber,et al.  Comparing Treatments Using Quality-Adjusted Survival: The Q-TWiST Method , 1995 .

[90]  C Chuang-Stein,et al.  A new proposal for benefit-less-risk analysis in clinical trials. , 1994, Controlled clinical trials.

[91]  R. Riegelman,et al.  Adjusting the Number Needed to Treat , 1993, Medical decision making : an international journal of the Society for Medical Decision Making.

[92]  E. Chelimsky,et al.  Cross-design Synthesis: A New Form of Meta-analysis for Combining Results from Randomized Clinical Trials and Medical-practice Databases , 1993, International Journal of Technology Assessment in Health Care.

[93]  H Raiffa,et al.  Decision Analysis: Introductory Lectures on Choices under Uncertainty. , 1969 .

[94]  C Chuang-Stein,et al.  Three measures for simultaneously evaluating benefits and risks using categorical data from clinical trials. , 1991, Statistics in medicine.

[95]  A. Fletcher Pressure to treat and pressure to cost: a review of cost-effectiveness analysis. , 1991, Journal of hypertension.

[96]  Judea Pearl,et al.  Probabilistic reasoning in intelligent systems - networks of plausible inference , 1991, Morgan Kaufmann series in representation and reasoning.

[97]  David M. Eddy,et al.  The Confidence Profile Method: A Bayesian Method for Assessing Health Technologies , 1989, Oper. Res..

[98]  Robert Cameron Mitchell,et al.  Using Surveys to Value Public Goods: The Contingent Valuation Method , 1989 .

[99]  P Glasziou,et al.  Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[100]  D L Sackett,et al.  An assessment of clinically useful measures of the consequences of treatment. , 1988, The New England journal of medicine.

[101]  D M Eddy,et al.  The value of mammography screening in women under age 50 years. , 1988, JAMA.

[102]  G. Carrin Economic evaluation of health care interventions: a review of alternative methods. , 1984, Social science & medicine.

[103]  R. L. Keeney,et al.  Decisions with Multiple Objectives: Preferences and Value Trade-Offs , 1977, IEEE Transactions on Systems, Man, and Cybernetics.

[104]  J. Linnerooth,et al.  The value of human life: a review of the models. , 1979, Economic inquiry.

[105]  John B. Kidd,et al.  Decisions with Multiple Objectives—Preferences and Value Tradeoffs , 1977 .

[106]  Payne Jt,et al.  A survey of the benefits and risks in the practice of radiology. , 1975 .

[107]  J. Payne,et al.  A survey of the benefits and risks in the practice of radiology. , 1975, CRC critical reviews in clinical radiology and nuclear medicine.